Literature DB >> 30242556

The importance of adequate methotrexate and adequate folinic acid rescue doses in the treatment of primary brain lymphoma.

Ian J Cohen1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30242556     DOI： 10.1007/s11060-018-2999-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  4 in total

1.  Factors Affecting the Upper Limit of the Methotrexate (MTX) CSF Levels Achievable in Children With Brain Tumors Treated With High-dose Intravenous MTX.

Authors:  Vered Shkalim Zemer; Helen Toledano; Shifra Ash; Eytan Cohen; Isaac Yaniv; Ian J Cohen
Journal:  J Pediatr Hematol Oncol       Date:  2016-10       Impact factor: 1.289

2.  Successful non-neurotoxic therapy (without radiation) of a multifocal primary brain lymphoma with a methotrexate, vincristine, and BCNU protocol (DEMOB).

Authors:  I J Cohen; R Vogel; S Matz; R Weitz; C Mor; S Stern; R Zaizov
Journal:  Cancer       Date:  1986-01-01       Impact factor: 6.860

3.  A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.

Authors:  Narayan Adhikari; Ahitagni Biswas; Ajay Gogia; Ranjit Kumar Sahoo; Ajay Garg; Ashima Nehra; Mehar Chand Sharma; Suman Bhasker; Manmohan Singh; Vishnubhatla Sreenivas; Rohan Chawla; Garima Joshi; Lalit Kumar; Subhash Chander
Journal:  J Neurooncol       Date:  2018-04-09       Impact factor: 4.130

Review 4.  Challenging the clinical relevance of folinic acid over rescue after high dose methotrexate (HDMTX).

Authors:  Ian J Cohen
Journal:  Med Hypotheses       Date:  2013-09-03       Impact factor: 1.538
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.